Editor’s Note
**Editor’s Note:** JSK Biomedical and Qstem have signed an MOU to jointly develop next-generation scalp care solutions, combining JSK Biomedical’s needle-free drug delivery platform ‘MIRAJET’ with Qstem’s hiPSC-based dermal papilla cell culture technology.
JSK Biomedical Co., Ltd. (CEO Jin-woo Jeon, hereinafter JSK Biomedical), developer of the needle-free drug delivery platform ‘MIRAJET’, announced on the 23rd that it has signed a Memorandum of Understanding (MOU) with Qstem (CEO Ki-won Ban), a company possessing hiPSC (human induced pluripotent stem cell)-based highly concentrated dermal papilla cell culture technology, for the joint development and business collaboration of next-generation scalp care solutions. JSK Biomedical holds the needle-free drug delivery platform ‘MIRAJET’.
Through this agreement, both companies will jointly pursue the development of scalp care products targeting professional institutions and the consumer market.
Under the agreement, JSK Biomedical will leverage its MIRAJET-based needle-free delivery technology to develop non-medical professional scalp care devices, while Qstem will provide highly concentrated dermal papilla cell culture fluid optimized for the devices. Based on this, the two companies will promote the commercialization of integrated scalp care solutions and jointly develop devices and ampoules suitable for both B2B and B2C markets. Additionally, they will conduct tests and evaluations on the local delivery efficiency and absorption characteristics of the needle-free delivery method.
Recently, in the scalp care market, the importance of delivery technology to enhance the performance of biomaterials has been growing. In particular, when combined with delivery technology, highly concentrated stem cell culture fluid can increase the utilization of active ingredients, making product development that integrates biomaterials and devices a new market direction attracting attention.
JSK Biomedical possesses needle-free delivery technology applicable to various liquid formulations based on the ‘MIRAJET’ platform. The related technology has been introduced in multiple SCI-level international academic journal papers, and recently, its application scope has expanded beyond the medical field to markets such as esthetics and home beauty.
Qstem is a specialized bio-company that has commercialized highly concentrated dermal papilla cell culture fluid based on the world’s first hiPSC-based dermal papilla cell platform technology. It has continuously accumulated R&D capabilities by publishing related research results in international academic journals and is accelerating full-scale commercialization by securing scientific evidence through joint research with major general hospitals such as Kangnam Sacred Heart Hospital and Sanggye Paik Hospital.
Under this agreement, JSK Biomedical will develop and supply non-medical professional needle-free scalp care devices based on MIRAJET optimized for Qstem’s ampoule specifications, and will pursue joint promotions utilizing its existing MIRAJET customer network (hospitals, clinics, etc.). Qstem will develop and supply hiPSC-based highly concentrated dermal papilla cell culture fluid ampoules, provide official data such as clinical studies and papers supporting the efficacy and effectiveness of the ampoules, and handle sales expansion through home shopping and online/offline channels.